drugset / Trial / NCT00354484

Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients

NCT00354484

Phase 3 Completed 291 enrolled American Regent, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIT45 compared to the current standard of care in postpartum patients.

Timeline

Start
2006-05
Primary completion
2006-12
Completion
2007-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 2500 mg Intravenous
Comparator Ferrous Sulfate Diagnostic / imaging agent 325 mg Oral

Indications

No indication recorded.